NOVARTIS is continuing to go for an indication for its new drug Ilaris ( canakinumab), a new injectable anti-inflammation drug given every 3 months. Paul Ridker met with Novartis' Ilaris team in south Florida a few weeks ago. He's following HsCRP or C Reactive Protein. He's published many times over the past 20 years re: measuring cv risk or heart attack/ stroke risk using HsCRP. Use Google Scholar and the keywords Paul Ridker and CRP to see many publications in this area.

The problems with serious infections still occur. See the Ilaris website for instructions on avoiding consequences of infections such as Tb, HIV, and hep C and B.

And, there is still the cost issue. In my 2nd video, I covered an article describing the $200,000/year cost of this medication. I have now found coupons on Drugs.com for injections bringing the cost to $80,000/year. This is getting interesting!

It's still less expensive - and safer - to prevent your heart attack, stroke, cancer the old-fashioned way - lose weight, don't smoke, exercise, eat right!